The Weekly Summary

Trump in IowaJanuary 25th – January 31st     2016

In the general news, the presidential debates and campaign dominated the slow news cycle. On the East Coast, the epic snowfall melted but caused DC to stay shut down most of the week.

In healthcare business news, earnings season kicked off. Medical devices seemed to be out of favor for many companies, such as JNJ. High drug prices drove growth in Pharma. HeartWare (HTWR) cancelled the planned deal with Valtech, and Gilead, (GILD) chose a new CEO. Lastly, MannKind (MNKD) is looking at options, such as selling the company.

On the data front, a panel recommended screening of pregnant women for depression. Also, Incyte (INCY) stopped a trial of Jakafi for colorectal cancer, sending shares down.

From the FDA, private Theranos was listed as a major threat to the public by federal inspectors. Also, Merck’s (MRK) won approval for new HCV drug Zepatier.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.